Table 2 Possible molecular targets for therapy in SSc
Target molecules | Available drug name | References |
|---|---|---|
Tyrosine kinases | Imatinib, Nilotinib, Dasatinib | Iwamoto N et al. Curr Rheumatol Rep. 2011;13:21 |
SRC kinases | SU6656, Dasatinib | Akhmetshina A et al. FASEB J. 2008;22:2214 |
TGF-b inhibitors | Several drugs | Asano Y. J Dermatol 2010;37:54 |
Histondeacetylase inhibitor | Trichostatin, SAHA | Huber LC et al. Arthritis Rheum 2007;56:2755 |
DNA Methyltransferase inhibitors | 5-AZA | Wang Y et al. Arthritis Rheum 2006;54:2271 |
Rho associated kinase | Fasudil | Akhmetshina A et al. Arthritis Rheum 2008;58:2553 |
Cannabinoid receptor 2 (CB2) agonists | Several drugs | Akhmetshina A et al. Arthritis Rheum. 2009;60:1129 |
PPAR γ agonists | None | Wei J et al. PloS One 2010;5:e13778 |
Adenosine A2A receptor blockers | None | Chan ES et al. Arthritis Rheum. 2006;54:2632 |
IL-13 inhibitors | None | Lafyatis R et al. Endocr Metab Immune Disord Targets 2006;6:395 |
Serotonin-Receptor-2B inhibitors | Terguride | Dees C et al. J Exp Med. 2011; 208:961 |
CTGF inhibitor | CTGF antibodies | Wang Q et al. Fibrogenesis Tissue Repair 2011;4:4 |
IL-6 receptor antagonist | Tocilizmab | Shima Y et al. Rheumatology(oxford) 2010;49:2408 |
MicroRNA-29a | None | Maurer B et al. Arthritis Rheum 2010;62:1733 |
Fos-Related Antigen-2 (AP-1 family) | None | Reich N et al. Arthritis Rheum 2010;62:280 Maurer B et al. Circulation. 2009;120:2367 |